The evolving regulatory/HTA interfaceunder the new European HTA Regulation

In an evolving ecosystem of decision making, close interaction between regulators and health technology assessment bodies is paramount to enable patient access to important new medicines and hence for the benefit of public health. This aims to generate evidence relevant for regulators, HTA bodies and other stakeholders thereby re-shaping and focusing medicine development programmes.

Furthermore, acknowledging the dependencies and remits, collaboration can also facilitate sequential decision-making by sharing information in the context of the respective assessments.

The webinar will focus on the newly evolving ecosystem in Europe, which provides unique opportunities for cooperation between the European Medicines Agency and the HTA Coordination group.